| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of 1 Neurological Surgery, 2 Biochemistry & Genetics, and 3 Molecular Pathology, Chiba University Graduate School of Medicine, Chiba, Japan
The biological features of gliomas, which are characterized by highly heterogeneous biological aggressiveness even in the same histological category, would be precisely described by global gene expression data at the protein level. We investigated whether proteome analysis based on two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry can identify differences in protein expression between high- and low-grade glioma tissues. Proteome profiling patterns were compared in 85 tissue samples: 52 glioblastoma multiforme, 13 anaplastic astrocytomas, 10 atrocytomas, and 10 normal brain tissues. We could completely distinguish the normal brain tissues from glioma tissues by cluster analysis based on the proteome profiling patterns. Proteome-based clustering significantly correlated with the patient survival, and we could identify a biologically distinct subset of astrocytomas with aggressive nature. Discriminant analysis extracted a set of 37 proteins differentially expressed based on histological grading. Among them, many of the proteins that were increased in high-grade gliomas were categorized as signal transduction proteins, including small G-proteins. Immunohistochemical analysis confirmed the expression of identified proteins in glioma tissues. The present study shows that proteome analysis is useful to develop a novel system for the prediction of biological aggressiveness of gliomas. The proteins identified here could be novel biomarkers for survival prediction and rational targets for antiglioma therapy.
This article has been cited by other articles:
![]() |
H. Okamoto, J. Li, A. O. Vortmeyer, H. Jaffe, Y.-S. Lee, S. Glasker, T.-S. Sohn, W. Zeng, B. Ikejiri, M. A. Proescholdt, et al. Comparative proteomic profiles of meningioma subtypes. Cancer Res., October 15, 2006; 66(20): 10199 - 10204. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Fukuda, Y. Iwadate, T. Machida, T. Hiwasa, Y. Nimura, Y. Nagai, M. Takiguchi, H. Tanzawa, A. Yamaura, and N. Seki Cathepsin D Is a Potential Serum Marker for Poor Prognosis in Glioma Patients Cancer Res., June 15, 2005; 65(12): 5190 - 5194. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Berchuck, E. S. Iversen, J. M. Lancaster, J. Pittman, J. Luo, P. Lee, S. Murphy, H. K. Dressman, P. G. Febbo, M. West, et al. Patterns of Gene Expression That Characterize Long-term Survival in Advanced Stage Serous Ovarian Cancers Clin. Cancer Res., May 15, 2005; 11(10): 3686 - 3696. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-y. Chuang, N. L. Tran, N. Rusk, M. Nakada, M. E. Berens, and M. Symons Role of Synaptojanin 2 in Glioma Cell Migration and Invasion Cancer Res., November 15, 2004; 64(22): 8271 - 8275. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |